146 related articles for article (PubMed ID: 34166982)
1. Multiple sclerosis and immune system biomarkers: Novel comparison in glatiramer acetate and interferon beta-1a-treated patient groups.
Pavelek Z; Novotny M; Soucek O; Krejsek J; Sobisek L; Sejkorova I; Masopust J; Kuca K; Valis M; Klimova B; Stourac P
Mult Scler Relat Disord; 2021 Aug; 53():103082. PubMed ID: 34166982
[TBL] [Abstract][Full Text] [Related]
2. A differential sex-specific pattern of IgG2 and IgG4 subclasses of anti-drug antibodies (ADAs) induced by glatiramer acetate in relapsing-remitting multiple sclerosis patients.
Avila S; Guerrero-García JJ; Becerril-Villanueva E; Pérez-Sánchez G; Pavón L; Rojas-Mayorquín AE; Mireles-Ramírez MA; Muñoz-Valle JF; Vallejo-Castillo L; Medina-Rivero E; Ortuño-Sahagún D; Pérez-Tapia SM
Mult Scler Relat Disord; 2019 Sep; 34():92-99. PubMed ID: 31272071
[TBL] [Abstract][Full Text] [Related]
3. Real-world propensity score comparison of treatment effectiveness of peginterferon beta-1a vs. subcutaneous interferon beta-1a, glatiramer acetate, and teriflunomide in patients with relapsing-remitting multiple sclerosis.
Reder AT; Arndt N; Roman C; Geremakis C; Mendoza JP; Su R; Makin C; Avila RL; Vignos MC
Mult Scler Relat Disord; 2021 Jun; 51():102935. PubMed ID: 33882426
[TBL] [Abstract][Full Text] [Related]
4. Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.
La Mantia L; Di Pietrantonj C; Rovaris M; Rigon G; Frau S; Berardo F; Gandini A; Longobardi A; Weinstock-Guttman B; Vaona A
Cochrane Database Syst Rev; 2016 Nov; 11(11):CD009333. PubMed ID: 27880972
[TBL] [Abstract][Full Text] [Related]
5. Interferon Beta-1a versus Glatiramer Acetate: Changes of Innate Immunity in a Group of Women with Multiple Sclerosis.
Peterka M; Valis M; Soucek O; Krejsek J; Sobisek L; Sejkorova I; Klimova B; Stourac P; Pavelek Z; Novotny M
Eur Neurol; 2023; 86(5):334-340. PubMed ID: 37473734
[TBL] [Abstract][Full Text] [Related]
6. Effects of interferon and glatiramer acetate on cytokine patterns in multiple sclerosis patients.
Ganji A; Monfared ME; Shapoori S; Nourbakhsh P; Ghazavi A; Ghasami K; Mosayebi G
Cytokine; 2020 Feb; 126():154911. PubMed ID: 31731047
[TBL] [Abstract][Full Text] [Related]
7. Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.
La Mantia L; Di Pietrantonj C; Rovaris M; Rigon G; Frau S; Berardo F; Gandini A; Longobardi A; Weinstock-Guttman B; Vaona A
Cochrane Database Syst Rev; 2014 Jul; (7):CD009333. PubMed ID: 25062935
[TBL] [Abstract][Full Text] [Related]
8. Assessment of CCL27 and IL-11 in Multiple Sclerosis Patients Treated with Interferon-β and Glatiramer Acetate.
Ebrahimi Monfared M; Shapoori S; Mosayebi G; Khansarinejad B; Ghazavi A; Rezagholizamenjany M; Ganji A
Neuroimmunomodulation; 2019; 26(6):301-306. PubMed ID: 31935737
[TBL] [Abstract][Full Text] [Related]
9. Monocyte and Lymphocyte Activation and Regulation in Multiple Sclerosis Patients. Therapy Effects.
González-Oria MC; Márquez-Coello M; Girón-Ortega JA; Argente J; Moya M; Girón-González JA
J Neuroimmune Pharmacol; 2019 Sep; 14(3):413-422. PubMed ID: 30649665
[TBL] [Abstract][Full Text] [Related]
10. Quality of life in people with multiple sclerosis receiving glatiramer acetate or interferon in Greek clinical practice.
Mitsikostas D; Bakirtzis C; Nikolaidis I; Tsimourtou V; Kountra P; Matsi S; Papadimitriou A
Neurodegener Dis Manag; 2022 Dec; 12(6):311-322. PubMed ID: 36178000
[TBL] [Abstract][Full Text] [Related]
11. B-Cell Activity Predicts Response to Glatiramer Acetate and Interferon in Relapsing-Remitting Multiple Sclerosis.
Tacke S; Braune S; Rovituso DM; Ziemssen T; Lehmann PV; Dikow H; Bergmann A; Kuerten S
Neurol Neuroimmunol Neuroinflamm; 2021 May; 8(3):. PubMed ID: 33707177
[TBL] [Abstract][Full Text] [Related]
12. Glatiramer acetate or IFN-β bridging therapy in women with relapsing multiple sclerosis planning a pregnancy.
Hellwig K; Thiel S; Haben S; Ciplea AI; Kurzeja A
Neurodegener Dis Manag; 2023 Aug; 13(4):223-234. PubMed ID: 37382065
[TBL] [Abstract][Full Text] [Related]
13. Effect of combined IFNbeta-1a and glatiramer acetate therapy on GA-specific T-cell responses in multiple sclerosis.
Dhib-Jalbut S; Chen M; Henschel K; Ford D; Costello K; Panitch H
Mult Scler; 2002 Dec; 8(6):485-91. PubMed ID: 12474988
[TBL] [Abstract][Full Text] [Related]
14. A prospective, open-label treatment trial to compare the effect of IFN beta-1a (Avonex), IFNbeta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing-remitting multiple sclerosis.
Khan OA; Tselis AC; Kamholz JA; Garbern JY; Lewis RA; Lisak RP
Eur J Neurol; 2001 Mar; 8(2):141-8. PubMed ID: 11284992
[TBL] [Abstract][Full Text] [Related]
15. Differential Transcription of SOCS5 and SOCS7 in Multiple Sclerosis Patients Treated with Interferon Beta or Glatiramer Acetate.
Rojas-Morales E; Santos-López G; Hernández-Cabañas S; Arcega-Revilla R; Rosas-Murrieta N; Jasso-Miranda C; El-Kassis EG; Reyes-Leyva J; Sedeño-Monge V
Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31905601
[TBL] [Abstract][Full Text] [Related]
16. Long-term follow-up of a randomized study of combination interferon and glatiramer acetate in multiple sclerosis: Efficacy and safety results up to 7 years.
Lublin FD; Cofield SS; Cutter GR; Gustafson T; Krieger S; Narayana PA; Nelson F; Salter AR; Wolinsky JS
Mult Scler Relat Disord; 2017 Nov; 18():95-102. PubMed ID: 29141831
[TBL] [Abstract][Full Text] [Related]
17. The effect of glatiramer acetate, IFNβ-1a, fingolimod, and dimethyl fumarate on the expression of T-bet, IFN-γ, and MEG3 in PBMC of RRMS patients.
Dabbaghi R; Safaralizadeh R; Rahmani S; Barpour N; Hosseinpourfeizi M; Rajabi A; Baradaran B
BMC Res Notes; 2023 Oct; 16(1):273. PubMed ID: 37845751
[TBL] [Abstract][Full Text] [Related]
18. Glatiramer acetate and IFN-beta act on dendritic cells in multiple sclerosis.
Hussien Y; Sanna A; Söderström M; Link H; Huang YM
J Neuroimmunol; 2001 Dec; 121(1-2):102-10. PubMed ID: 11730946
[TBL] [Abstract][Full Text] [Related]
19. A comparison of the mechanisms of action of interferon beta and glatiramer acetate in the treatment of multiple sclerosis.
Zhang J; Hutton G; Zang Y
Clin Ther; 2002 Dec; 24(12):1998-2021. PubMed ID: 12581542
[TBL] [Abstract][Full Text] [Related]
20. Production of brain-derived neurotrophic factor by mononuclear cells of patients with multiple sclerosis treated with glatiramer acetate, interferon-beta 1a, and high doses of immunoglobulins.
Sarchielli P; Zaffaroni M; Floridi A; Greco L; Candeliere A; Mattioni A; Tenaglia S; Di Filippo M; Calabresi P
Mult Scler; 2007 Apr; 13(3):313-31. PubMed ID: 17439900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
